Bernstein lowered the firm’s price target on BioMarin (BMRN) to $88 from $95 and keeps a Market Perform rating on the shares following quarterly results. The firm notes BioMarin delivered an in-line revenue print but missed on EPS due to consensus mis-modeling of AIPR&D for inozyme.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin: FDA accepts for Priority Review sBLA for Palynziq
- Biomarin’s Acquisition Strategy: Navigating Risks and Challenges for Future Growth
- BioMarin’s Earnings Call: Growth Amid Challenges
- BioMarin price target lowered to $80 from $90 at Truist
- BioMarin price target lowered to $66 from $70 at RBC Capital